Case | HBS Case Collection | September 2005 (Revised June 2006)

WuXi PharmaTech

by Richard G. Hamermesh and Simin Zhou

Abstract

WuXi Pharmatech has gone from zero to $21 million in sales in three years. The company must decide its growth strategy and how best to finance and organize for rapid growth.

Keywords: Growth Management; Capital Markets; Problems and Challenges; Pharmaceutical Industry; China;

Citation:

Hamermesh, Richard G., and Simin Zhou. "WuXi PharmaTech." Harvard Business School Case 806-003, September 2005. (Revised June 2006.)